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Pancreatic neuroendocrine tumors are a group of endocrine tumors that  
constitute 7% of all pancreatic neoplasms. They can be benign or malignant. Their 
presentation can vary from slow growing, non infiltrative, indolent masses to 
rapidly progressing, highly aggressive, metastasizing tumors. In the past, there 
was paucity of scientific data available about the diagnosis and treatment strategy 
of these neoplasms but in recent years, ongoing research has inferred much data 
regarding classification, prognostic stratification and therapy of pancreatic neuro-
endocrine tumors. In this chapter we will discuss epidemiology, clinical presenta-
tion and classification, diagnosis and management of these tumors. We will also 
deliberate about the latest developments in treatment of pancreatic neuroendocrine 
tumors with focus on recent studies done on this topic.
Keywords: pancreatic neuroendocrine tumors, pancreatic NET, GEP-NET, 
Gastroenteropancreatic tumor
1. Introduction
Neuro-endocrine tumors constitute 0.5% of all malignancies [1]. Gastro-
entero-pancreatic neuro-endocrine tumors (GEP-NET) originate from 
neuro-endocrine cells of the embryological gut and they constitute a group of 
heterogeneous tumors that demonstrate divergent tumor biology, different diag-
nostic behavior, management principles and tumor-patient outcomes [2].
2. Incidence and epidemiology
GEP-NET comprises 2% of all gastrointestinal tumors [3]. Pancreatic neuroen-
docrine tumors (PNETs) are one of the most common neuroendocrine tumors [4]. 
But they are relatively rare tumors and comprise about 7% of all cancers that occur 
in the pancreas [5]. According to The American Cancer Society’s estimates for 2020, 
about 4,032 people in the United States will be diagnosed with pancreatic NET.8
With better imaging modalities coming into play, the incidence of pancreatic 
NETs is increasing over the years as they are often found incidentally when radio-
logical tests such as CT or MRI scans are done for other diseases. There has also 
been increased sensitivity of lab tests that have escalated the ability to distinguish 
these tumors from other malignancies. The increased prevalence over the past few 
decades, is attributed to multifactorial causes mainly as a consequence of increased 
awareness and improved diagnostic technique [6]. It is estimated that nowadays 
almost 50% of PNET diagnoses are incidentalomas [7]. An aging population and 
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heightened awareness of the disease have also contributed to an increase in the 
detection of incidentalomas [8].
Majority of pNET are sporadic, i.e. non inherited while 10–30% pNET are 
associated with a genetic syndrome like multiple endocrine neoplasia (MEN) type 1, 
which is most commonly associated with it [9]. Other rare genetic conditions include 
MEN4, Von Hippel–Lindau disease, neurofibromatosis 1 (von Recklinghausen’s 
syndrome), and tuberous sclerosis, which are linked to genetic type pNET [10].
There is no gender predilection for pNET although some studies have sug-
gested a slight preponderance for men. These tumors can present at any age but the 
incidence of sporadic tumors rises from fifth decade and peaks around 80s [11].
3. Classification and staging
In the past NETs were classified based upon the site of origin in embryological 
gut as foregut, midgut and hindgut tumors. It has been rather challenging to clas-
sify these tumors due to their heterogeneity, difference in their morphology, clinical 
presentation, molecular biology, hormone profile and treatment response.
Clinically these tumors have been classified as functioning and non functioning 
tumors. In 2007 WHO introduced a new classification system for neuroendocrine 
tumors which categorized them according to tumor’s proliferation indices like mitotic 
index or Ki67 score as well differentiated tumors and poorly differentiated carcinomas 
[12]. In 2010 it also included histopathological features as a criteria for classification 
apart from proliferation indices, which lead to revision of the existing guidelines 
and NETs were further divided into three grades based upon ENETS classification 
(Table 1) [14]. Well differentiated tumors comprised of grade 1 and grade 2 NET, 
while poorly differentiated tumors were grade 3 NET also described as neuroendocrine 
carcinoma (NEC). The difference between the two has been illustrated in Table 2 [14].
In 2017, the classification was re-revised to include NET grade1, 2 and 3 in the  
well differentiated category and the poorly differentiated category was NEC grade 3. 
See Table 3 [15].
European neuroendocrine society has also devised a staging for GEP-NET. 
American cancer society has included tumor resectability as classification criteria 
(Figure 1) [17].
Mixed adenoneuroendocrine carcinoma (MANEC) of pancreas are a group of 
extremely rare tumors, with incidence approximately 0.2% and only a few cases are 
reported in literature [18]. They have both adenocarcinoma and neuroendocrine 
components with each component accounting for more than 30% of the tumor [19]. 
Due to rarity of this, tumor the clinical behavior is not studied much. It has been 
proposed that the treatment should depend on the aggressiveness of the cell type 
of the tumor [20]. In various cases studied, surgery has been considered as the first 
line of treatment for resectable tumors. Post operative treatment includes adjuvant 
chemotherapy and/or radiotherapy [21].
Well differentiated net Ki67 index Mitotic index
NET G1 <=2% <2/hpf




Who classification 2010 [13].
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Characteristics NET G3 NEC
Pathological differentiation Well differentiated Poorly differentiated
Ki 67 index >20% (usually 30–55%) >20%(usually 50%)
Mitotic index >20/hpf >20/hpf
necrosis Rare present
Genetic syndrome MEN1, VHL occasionally rare
Functionality occasionally rare
Neuroendocrine marker expression positive weak
Somatostatin receptor scintigraphy uptake strong weak
Loss of ATR x and DAXX protein expression present rare
Abnormal p53, SMAD4 and Rb expression rare present
Response to platinum agents worse better
Prognosis Relatively good poor
Table 2. 
The difference between NET Grade3 and NEC grade3 [15].
Well differentiated net Ki67 index Mitotic index
NET G1 <3% <2/hpf
NET G2 3–20% 2–20/hpf




Who classification 2017 [13].
Figure 1. 
Comparison of TNM classification of pancreatic NENs according to ENETS versus UICC/AJCC (TNM 
classification) [16].
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4. Etiopathogenesis
4.1 Cellular biology of net
As such pNETs were classically thought to arise from pancreatic islet cells or the 
islets of Langerhans, hence the term islet cell tumors was coined [22]. Islet cells are 
the endocrine cells of the pancreas and they constitute 1–2% of total pancreatic 
mass. They are therefore distinct from the exocrine cells, from which pancreatic 
ductal adenocarcinomas arise. They are composed of various cell types and respon-
sible for secretion of hormones like beta cells (insulin), alpha cells (glucagon), delta 
cells (somatostatin), and PP cells (pancreatic polypeptide) [23]. However, current 
theory says that pNETs in fact arise from the APUD (amine precursor uptake and 
decarboxylation) cells [24]. The presence of neurosecretory granules is the char-
acteristic feature of APUD cells and these neurosecretory granules have autocrine, 
paracrine and neuromodulatory functions, in addition to the endocrine property. 
These cells are thought to originate in the embryologic neural crest, but more recent 
research suggests that they originate in the embryologic endoderm [25].
The most common genes involved in pancreatic neuroendocrine tumors are 
mentioned in Table 4.
Other specific genes suggested to be implicated in the etiopathogenesis of NETs 
include BIN1, Serpine 10, BST2, IGFBP3, LCK, MET, fibronectin, PDGF, IGF- 1, fibro-
blast growth factor, TGF-alpha and–beta, EGFR, and stem cell factor receptor [27].
Multiple studies have elucidated the underlying genetic mechanism regarding 
molecular development and progression of these tumors but still much remains 
unexplored in this area. Loss of chromosomes 3q, 6pq, and 10 pq, and gains of 5q, 
12a, 18q, and 20q is associated with malignant behavior in these tumors [28]. In 
tumors less than 2 cm in size, it has been observed that Chromosome 1 and 11q loss 
with gain of 9q is associated with genetic instability [29].
4.2 Olecular pathology of PNET and its role in prognosis
Most recent advancements in assessment of pancreatic NET is the development 
of microRNA profiling which corresponds to various proliferation indices and also 
propensity of tumor to cause local spread and distant metastasis [30]. MicroRNA 
are non-coding RNA sequences having length of 21–25 nucleotides. They regulate 
genes at post translational level [31]. They can act as oncogenes or tumor suppressor 
genes and play a significant role in proliferation of tumors or their dissemination 
[32]. They can act as diagnostic as well as a prognostic marker.
There is very limited data available regarding microRNA profiling of pNET. 
In one large study done on pancreatic NET, 28 different miRs have been shown to 









Common genes in pancreatic neuroendocrine tumors vs. pancreatic adenocarcinoma [26, 27].
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be differentially expressed with 18 of them being higher expressed and 10 lower 
expressed as compared to healthy pancreatic tissue [33]. There is a higher expres-
sion of miR-103, miR-107 and miR-193b and lower expression of let-7 miR and 
miR-155 in pancreatic neuroendocrine neoplasias [34]. Tumor proliferation is 
denoted by expression levels of miR-196a, miR-21 and miR-642 while miR-210 and 
miR-21 seem to correlate with metastatic disease and tumor recurrence is predicted 
by expression of both miR-196a and miR-27b [35, 36].
Circulating tumor cell count also plays an important role in delineating the 
prognostic value of pNETs, especially before and during the treatment. Liquid 
biopsy is emerging as a newer and more profound biomarker test which provides 
valid cytochemical, morphological, pathological and molecular information 
regarding response of anti tumor therapy for pNET [37]. Circulating tumor cells 
(CTC) are shed from the primary or metastatic component of the tumor and they 
are evaluated by liquid biopsy [38]. CTC are considered as prognosticators in many 
solid malignancies but their role in neuroendocrine tumors was highlighted first 
by Khan et al. in 2011 [39] patients with advanced NETs who were starting either 
systemic or local therapy were enrolled. It was found that patients with one or more 
circulating tumor cells (CTC) were more likely to have worse progression free and 
overall survival.
Further placental growth factor (PIGF) is also evaluated as a prospective 
biomarker in NET. pIGF is a derivative of VEGF, which shows increased expression 
in NETs. It was found that PlGF levels were elevated in pNET samples and serum 
as compared to control pancreatic tissue and control serum. It was concluded that 
elevated PIGF levels are seen in pNET and it has also been projected that increase 
PIGF levels correlate with shorter time to progression [40].
5. Clinical presentation
Since non functional pNET represent up to 90% of PanNETs, they present  
with high hormone levels without symptoms. However, upto 60% of these 
patients have a metastatic disease at diagnosis, while 21% present with a locally 
advanced disease [41].
Non specific symptoms of pNET include abdominal pain, weight loss, or mass 
effect related to the pancreatic tumor or to the distant spread. Less frequently it is 
associated with complaints of jaundice, hemorrhage from tumors, and a palpable 
mass. Symptoms often do not appear until metastases develop [42].
Usually endocrine tumors of the pancreas present with typical symptoms due to 
hormonal hypersecretion, such as insulinoma, gastrinoma, VIP-oma, glucagonoma 
and somatostatinoma. In upto 40%-50, cases may present as non-functioning 
tumors or secrete pancreatic polypeptide (PP) and neurotensin [43]. The various 
pancreatic NET subtypes with their incidence, clinical presentation and survival are 
mentioned below (Table 5).
6. Diagnosis
6.1 Biochemical
Chromogranin A is a secretory glycoprotein present in neurosecretory granules 
of pancreatic NET. Majority of pNET show elevated chromogranin A levels. The 
sensitivity depends upon the tumor burden and the levels of chromogranin A 











Tumor/Syndrome Incidence Associated Symptoms Malignancy Associated peptide Survival
Insulinoma [45]/ 
Hypoglycemia Syndrome
1–4 per million 
per year
Confusion, sweating, dizziness, 
weakness, relief with eating
10% patients develop metastasis insulin Complete resection leads to cure
Gastrinoma [46]/zollinger 
ellison syndrome
1–2 per million 
per year
Diarrhea with or without severe 
peptic ulcertion
60% patients develop metastasis, 
likelihood correlated with size of 
primary
gastrin Complete resection leads to 
10 year survival 90%
Glucagonoma [47] 0.1 per million 
per year
Weight loss, diabetes 
mellitus,necrolytic migratory 
erythema
60% patients develop metastasis glucagon Most favorable prognosis with 
complete resection, even in cases 
with liver metastasis
VIPoma [48]/ verner 
morrison syndrome







Complete resection associated 
with 5 year survival 95%,
With metastasis 60%
Somatostatinoma [49] 1 in 40 million Cholelithiasis, weight loss, 
steatorrhea, diarrhea, diabetes 
mellitus, achlorhydria
50% patients develop metastasis Somatostatin Complete resection associated 
with 5 year survival 95%,,
With metastasis 60%
ACTHoma [50] <0.1 Cushing syndroma ACTH
PTHrPoma/ pNET causing 
hypercalcemia [32]
<0.1 Symptoms due to raised Ca levels PTHrP
GRFoma [32] <0.1 acromegaly GRF
Non syndromic pancreatic 
neuroendocrine syndrome 
[32]
Symptoms due to pancreatic mass or 
liver metastasis
50% patients develop metastasis Complete resection associated 
with 5 year survival 50%
Table 5. 
Incidence, clinical presentation and survival of pancreatic NET subgroups [27–32, 44].
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chromogranin A levels are rare. Other serologic markers include neuronal serum 
enolase, human chorionic gonadotropin, and pancreatic polypeptide, which are 
elevated in 20–40% of PNETs. (See Table 6) [52].
When any NET is suspected then fasting gut hormones such as chromogranin 
B, pancreatic polypeptide and urinary 5HIAA (a breakdown product of serotonin) 
are also useful baseline tests. False positive chromogranin A levels are caused due to 
treatment with a proton pump inhibitor, Parkinson’s disease, hypertension, glu-
cocorticoids, renal failure and atrophic gastritis, while various dietary factors and 
drugs can cause an elevated urinary 5HIAA [53].
Additional blood tests for secreted peptides can be useful if a clinical syndrome 
is suspected and calcium, prolactin and parathyroid hormones should be tested in 
possible MEN1 cases. For Nonfunctioning pNETs, pancreatic polypeptide is a useful 
test. For insulinomas the gold standard diagnostic tool is supervised fasting with 
serial blood glucose analysis. Diagnosis requires the fulfillment of Whipple’s triad of 
hypoglycemia, symptoms and correction of symptoms with glucose, in the presence 
of non-suppressed insulin levels. Factitious hypoglycemia due to administration of 
insulin or sulfonylureas must be ruled out [54].
6.2 Radiological
Cross sectional imaging plays an important role in the workup of PNETs by 
characterizing the primary tumor and determining the extent of disease. Location 
of the tumor and its spread can be delineated by the use of multimodality imaging 
which includes computed tomography (CT), MRI and various nuclear medicine 
scans. Endoscopic ultrasound (EUS), digital subtraction angiography and venous 
sampling can also be used [55]. The sensitivity of CT and MRI is more than 80% for 
the detection of PNETs which is more sensitive than an octreotide-based scinti-
graphic scans [56].
EUS acts as an indispensable accompaniment to CT or MRI and has superior 
resolution. For tumors with size as small as 2 mm, EUS shows sensitivity of 
more than 90% and when combined with cross sectional imaging the sensitiv-
ity reaches upto 100%. Addition of EUS is recommended when cross-sectional 
imaging fails to define the pancreatic mass, when the location of primary cannot 





Raised basal serum gastrin,
High gastric acid secretion
Insulinoma Fasting Insulin, Glucose, C peptide 
(sulfonyl urea screen negative)
Raised fasting insulin/glucose ratio, 
proinsulin or c peptide
Glucagonoma Fasting gut hormones, ski biopsy Raised serum pancreatic glucagons 
and enteroglucagon
VIPoma Fasting gut hormone Raised fasting VIP
Ppoma Fasting gut hormone Raised fasting pancreatic polypeptide
Somatostatinoma Fasting gut hormone Raised fasting somatostatin
All NET Serum chromogranin Raised chromogranin A
Ectopic hormones GHRH, ACTH, HCG-alpha and beta Raised but low incidence
Table 6. 
Biochemical tests for pNET [33, 51].
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Since NETs have high levels of somatostatin receptor 2 (SSTR2) expression, 
Functional imaging comes into play in these tumors. For tumors lacking SSTR2, 
like insulinomas and poorly differentiated tumors, it is less useful [58]. It is used 
to detect primary tumors or metastatic disease which is not readily seen on cross-
sectional imaging. Also, the uptake can predict response to octreotide analogs [59].
Indium-111 (111In) pentetreotide scan (Octreoscan) is a readily available nuclear 
scan that is effective at identifying nonfunctional PNETs, glucagonomas, and 
gastrinomas [60]. Although High-resolution positron emission tomography (PET) 
in combination with CT is superior in detecting small tumors and identifying occult 
metastases as compared to 111In pentetreotide. For identifying well-differentiated 
NETs, Octreoscan appears more sensitive than (18) FDG-PET, whereas (18) FDG-
PET demonstrates superior sensitivity for poorly-differentiated NETs [61].
Somatostatin receptors are overexpressed in a proportion of NETs and 
Somatostatin receptor scintigraphy (SSRS) is useful in detecting these tumors. 
There are five subtypes of SSTR and 80% of pNETs, excluding insulinomas, express 
SSTR-2. Less than half of insulinomas express SSRT-2, therefore Single-photon 
emission computed tomography (SPECT) has sensitivity of 50% when combined 
with SSRS. In gastrinomas, VIPomas, glucagonomas and nonfunctional tumors 
SSRS combined with SPECT has a diagnostic sensitivity of 75% [20].
Currently both 18F-FDG PET/CT and 68Gallium (Ga)-labeled somatostatin 
analog PET/CTs such as 68Ga-DOTATOC or 68Ga-DOTATATE PET/CTs are used. 
FDGPET use is limited to poorly differentiated NETs, as well differentiated NETs 
are not FDG avid. It may also be used to demonstrate aggressive behavior or het-
erogeneity between lesions in a single patient. 68Ga-labeled somatostatin analog 
PETs have been shown to be superior to CT or SSRS in sensitivity and specificity, for 
detecting an unknown primary, staging at diagnosis, and for follow-up [62].
6.3 Histopathology
They can be classified as well differentiated and poorly differentiated NET. the 
major differences are elaborated further (Table 7).
7. DIfferential diagnosis
• Acinar cell carcinoma: It can be differentiated from pNET as it has 
granular PAS positive cytoplasm, BCL10, trypsin, chymotrypsin positive, 
Synaptophysin and chromogranin positivity <25% while pNET is PAS negative, 
Well Differentiated Net [63] Poorly Differentiated Net [64]
• “organoid” arrangements of the tumor cells
• solid, nested, trabecular, or ribbon-like/gyriform, tubulo-
acinar/pseudoglandular and mixed pattern
• Uniform cells with round to oval nuclei, coarsely granular, 
‘salt and pepper’ chromatin
• pale to moderately eosinophilic cytoplasm
• Has neurosecretory granules
• Necrosis absent
• Sheets or nests of atypical cells
• pleomorphic, hyperchromatic nuclei 
and abundant mitotic figures
• ‘Salt and pepper’ appearance of 
chromatin is absent
• Necrosis often present
• small cell (molding nuclei, scant 
cytoplasm) or large cell (abundant 
amphophilic cytoplasm
Table 7. 
Histopathological features of well and poorly differentiated tumors.
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BCL10, trypsin, chymotrypsin negative and Synaptophysin or chromogranin 
positivity over 25% [65].
• Solid-pseudopapillary neoplasm: It has pseudopapillary architecture, 
Chromogranin focal to negative, Galectin 3,Vimentin, CD10, Nuclear 
beta catenin positive while pNET has no pseudopapillary architecture, 
Chromogranin strongly positive, Galectin 3,Vimentin, CD10, Nuclear beta 
catenin negative [65].
• Pancreatoblastoma: It shows Trypsin, chymotrypsin positive, Chromogranin, 
synaptophysin scattered positive, Islet polypeptide markers negative or very 
focal while Trypsin, chymotrypsin negative, Chromogranin or synaptophysin 
widespread staining, Islet polypeptide markers frequently positive in pNET [65]
Insulinoma [27]: the differential diagnosis includes conditions with increased 
insulin levels in blood
• Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)
• Sulfonylurea-induced hypoglycemia
• Insulin autoimmune hypoglycemia
• Post-gastric bypass hypoglycemia
• Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS)
• Non-islet-cell tumors that secrete insulin-like growth factors (IGF)









• Type 1 and 2 Diabetes Mellitus
8. Management
Multidisciplinary teams (MDTs) have an important role in deciding the treat-
ment of these tumors as they are slightly rare.
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Treatment options range from curative surgery to palliation with medical thera-
pies including somatostatin analogs, chemotherapy and targeted treatments [67].
Conservative management is indicated for incidentalomas, i.e. the tumors which 
are small, non functional and asymptomatic [68]. Although it is a controversy 
whether small nonfunctional tumors of under 2 cm should be resected, when they 
are likely to have less metastatic potential, but a more aggressive surgical approach 
is recommended for tumors over 2 cm [69].
8.1 Surgery
Surgery is the only curative treatment option and should be considered in all 
patients with localized disease as it not only cures the mass related symptoms but 
also the hormone related effects. Such patients should have their surgery carried out 
at specialist hepatopancreatobiliary centers. Surgery can be done for curative treat-
ment like radical excision or palliative treatment that aims for symptomatic relief. It 
can also be used for surgical treatment of complications. The 5-year overall survival 
rate of resected PNETs is significantly greater than unresected ones, ranging from 
77% to 46% [70]. Unfortunately, pancreatic surgery shows significant mortality, 
ranging from 1% to 10% [71] and morbidity. The perioperative and long-term 
complications include diabetes, pancreatic exocrine impairment in up to 50–60% 
patients, even in high volume centers [72, 73].
Careful observation and wait and watch policy can be employed for small non 
functioning pNET which helps in not only avoiding the pancreatic surgery but also 
helps curb the operation related complications, as most of the small NF-PanNETs 
are indolent despite a chance of 10% of nodal involvement [74, 75].
According to the updated ENET guidelines patients having NF-PanNETs ≤2 cm 
can be safely managed conservatively.
Indications of non operative approach:
• the presence of G1-low G2 tumor
• Tumor localized to pancreatic head
• no signs of malignancy at imaging.
In patients with G2 NF-PanNETs greater than or equal to 2 cm, surgery should 
be recommended. Other factors to be taken into consideration include patient’s age, 
comorbidities, surgical risk, the tumor site, and desire for surgical intervention.
In cases of surveillance, EUS and MRI should be mandatory and to be repeated 
every 6 months (12 months if no changes are discovered). If an increase of 0.5 cm 
(or more) in the size of the lesion is seen on the imaging then the patient should be 
reevaluated for surgery [9].
The studies comparing observation with surgery in pNET are as 
follows:(Table 8).
In contrast to the ENETS guidelines, the American National Comprehensive 
Cancer Network (NCCN) guidelines recommend surgery to be done in a pNET 
bigger than 1 cm. Observation is indicated incidentally discovered, low-grade 
NF-PanNETs smaller than 1 cm. Additional factors for conservative management 
include the surgical risk, the tumor site, and the patient comorbidities, especially 
when dealing with small asymptomatic tumor [80]. NCCN states that more aggres-
sive approach (routine surgery) is recommended in tumors greater than 1 cm as 
some small (<2 cm) high-grade tumors demonstrate frankly malignant behavior 
(9% to 39%) [81].
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8.2 Systemic therapy
In patients with resectable PanNETs, surgery with curative intent (that is, R0 or 
margins that are microscopically free of tumor) remains the treatment of choice. 
Unfortunately, as the majority of patients with PanNETs either present with meta-
static disease or have disease recurrence within 2 years of surgery, effective systemic 
therapies are also needed [82].
8.3 Somatostatin analogs
Somatostatin analogs remain the cornerstone in treatment of advanced neuroen-
docrine tumors.
Long acting octrotide, lanreotide which bind both SSTR2 and SSTR5 and pasire-
otide which binds to SSTR1, 3, and 5 are currently approved for clinical use [83].
Trials studying the role of somatostatin analogues (Table 9).
Study No. of patients Protocol Result
Sadot et al. [76] Incidentally 
discovered, sporadic, 





vs. surgery 77 
patients
No diff in os in both groups





vs. surgery 20 
patients
Incidentally discovered NF-PNETs 
<2 cm in size can be observed safely 
with serial imaging.




patients vs. 10 
surgery
Tumor size has great impact on 
malignancy. he cutoff of 2 cm 
of malignancy used for small 
NF-PNETs could be decreased 
to 1.7 cm to select patients more 
accurately.





Resection of nonfunctioning PNETs 
over 1.5 cm is independently and 
significantly associated with a 
longer survival
Table 8. 
Studies comparing observation versus surgery in small pNET.
Study No. of patients Protocol Result
PROMID 
TRIAL [84]







time to tumor progression 
compared with placebo.
















Studies showing role of somatostatin analogues in pNET.
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The use of pasireotide, a somatostatin analog was evaluated in a phase III 
randomized trial targeting SSTR5, in octreotide-resistant patients. It demonstrated 
no difference in the response rate (RR) compared with long-acting octreotide. The 
trial was stopped prematurely [86].
Chan et al., studied 1022 patients in 18 trials using more than 30 mg octreotide 
or 120 mg lanreotide over 28 days in a meta-analysis in 2017 [87]. Pasireotide 
has shown a more potent antiproliferative effect as compared to octreotide in 
preclinical data from NCI-H727 cells and from pancreatic NET primary cell 
cultures [88].
A similar study conducted by Cives et al. recently showed that pasireotide 
LAR provides better tumor control efficacy (PFS 11 months), when used as 
first-line therapy in patients with advanced NET [89]. Further, in patients with 
functionally active advanced GEP-NETs, pasireotide provided an improved 
tumor control rate at 6 months compared to octreotide [50]. In 160 patients 
with progressive grade 1 through 2 pancreatic NETs, the COOPERATE-2 trial 
tested the combination of everolimus and pasireotide vs. everolimus. It was 
seen that both overall and progression-free survival were similar in both arms 




No of patients protocol Result
Kulke et al. 
2008 [91]
Phase 2





oral sunitinib ORR) in pancreatic endocrine tumor 
patients was 16.7%
SD68%




171 patients Placebo (n = 85) vs. 
sunitinib(n = 86)
Median PFS was 11.4 months in the 
sunitinib group as compared with 
5.5 months in the placebo group.
objective response rate was 9.3% in 
the sunitinib group versus 0% in the 
placebo group







Median PFS 16.7 mo.
Yao et al. 
[94]
Phase 2
30 patients Everolimus + 
octreotide LAR
Median PFS 12.5 mo.
Yao et al. [95]
Phase 3
410 patients Everolimus (n = 207) 
vs. placebo (n = 203)
Median PFS 11 mo vs. 4.6 mo.
Duran et al. 
[96]
Phase 2
15 patients temsirolimus median TTP 6 months and 1-year OS 
rate 71.5%
Hobday et al. 
[97]
Phase 2
43 patients sorafenib Median PFS 6 month
Phan et al. 
[98]
Phase 2




Studies showing the role of targeted therapy in treatment of pNET.
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8.4 Targeted therapy
Molecular targeted therapies have emerged as a promising treatment modality 
for patients with well-differentiated PNETs in which disease progression is seen on 
a somatostatin analog or who are on best supportive care. Randomized studies have 
shown an improvement in PFS but not OS. Currently, sunitinib and everolimus are 
approved for use in PNETs (Table 10).
8.5 Cytotoxic chemotherapies
Much of the focus on treatment over the past half century has been on the use of 
conventional cytotoxic agents such as streptozocin [99] and temozolomide [100]. 
Sunitinib and everolimus are approved for use in PNETs (Table 11).
8.6 Peptide receptor radionuclide therapy (PRRT)
Majority of neuroendocrine tumors show increased level expression of soma-
tostatin receptors (SSRs) 2 and 5 on the tumor cell surface and it forms the basis 
Study Design No of patients protocol Result
Broder et al. [63]
Phase 2
52 streptozocin A significant increase in 
1-year survival rate and 
a doubling of median 
survival were shown for the 
responders as compared 
with the nonresponders
Moertel et al. [101]
Phase 3
84 Streptozocin (n = 42) vs. 
streptozocin plus 5FU 
(n = 86)
Median OS was 26.5 months 
in the streptozocin plus 
5FU group as compared 
with 16.5 months in the 
streptozocin group






Median OS 16.8 mo.
Median OS 18 mo
Moertel et al. [103]
Phase 2
14 Cisplatin + etoposide




Ramanathan et al. 
[105]
50 Dacarbazine median OS 19.3 months
Bajetta et al. [106] 27 Capecitabine/oxaliplatin
Kulke et al. [107]
Phase 2
11 Temozolomide/thalidomide Median OS 24 months
Chan et al. [108] 15 Bevacizumab Plus 
Temozolomide
median overall survival was 
41.7 months for pancreatic 
NETs
Chan et al. [109] 43 Temozolamide and 
everolimus
the median progression-
free survival duration was 
15.4 months. Median overall 
survival was not reached
BETTER trial [110] 34 Bevacizumab with 5-FU/
streptozocin
Median PFS 23.7 months
OS rate at 24 months was 
88%.
Table 11. 
Studies showing role of cytotoxic chemotherapy in pNET.
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of not only functional imaging but also tumor directed therapies like somatostatin 
analogues [111]. Beyond somatostatin analogues, PRRT, which is described as 
peptide receptor radioligand therapy or targeted radiotherapy using radiolabeled 
somatostatin analogs is emerging as an effective treatment modality in metastatic, 
well-differentiated, grade 1 and 2 GEP-NET [112]. Yttrium, a high-energy β particle 
emitter and Lutetium, a β and γ particle emitter with lower tissue penetration are 
most commonly studied radioligands [113] (Table 12).
131I-metaiodobenzylguanidine (131I-MIBG) therapy has shown promise in 
in MIBG positive metastatic neuroendocrine tumors, in addition to radiolabeled 
somatostatin analogs [121].
The toxicities associated with PRRT include myelosuppression and nephrotoxic-
ity, both of which are reversible, acute pain due to radiation edema and nausea and 
vomiting, associated with the use of amino acids to reduce the risk of nephrotoxic-
ity and very rarely myelodysplastic syndrome.
9. Prognosis
Depends upon Metastatic spread, large tumor size, and hormonal hypersecre-
tion as well as gender, age, and histopathological high-grade, Ki67 (Table 13).
10. Conclusion
Pancreatic neuroendocrine tumors are a distinct group of tumors from other 
pancreatic malignancies. They present with vastly different spectrum of clinical 
Study No. of Patients Radioligand Result
Valkema et al. [114] 58 90Y-DOTATOC PFS 29 months
OS 17 months
Kwekkeboom et al. [115] 310 177Lu-DOTATATE PFS 33 months
OS 46 months
Bushnell et al. [116] 90 90Y-DOTATOC PFS 16 months
OS 27 months
Cwikla et al. [117] 58 90Y-DOTATATE PFS 17 months
OS 22 months
Pfeifer et al. [118] 53 90Y-DOTATOC PFS 29 months
OS - months
Bodei et al. [119] 39 177Lu-DOTATATE PFS 36 months
OS - months
Ezziddin et al. [120] 74 177Lu-DOTATATE PFS 26 months
OS 55 months
Table 12. 
Various retrospective studies have been conducted on PRRT.




All SEER stages combined 54%
Table 13. 
5-year relative survival rates for pancreatic NET [8].
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features ranging from asymptomatic incidentalomas to symptoms related to hor-
mone hypersecretion or due to mass effect. Due to rarity of these tumors and as the 
biological potential of these tumors remain unexplored, the management is largely 
consensus based and is still under a lot of research. Although surgery is the main 
modality of treatment but conservative management is also indicated in small non 
functioning tumors. Advanced pNET can be treated with chemotherapy or targeted 
agents. In this context, prospective studies with the creation of a large multi-center 
trials and an international registry are future recommendations.
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